相似文献
1
Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas.
Intern Med. 2021 Aug 15;60(16):2607-2612. doi: 10.2169/internalmedicine.6755-20. Epub 2021 Mar 1.
2
Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?
J Clin Oncol. 2023 Apr 10;41(11):1972-1975. doi: 10.1200/JCO.23.00039. Epub 2023 Feb 28.
3
[A Case of Unresectable Pancreatic Cancer with Massive Cancerous Ascites Responsive to KM-CART].
Gan To Kagaku Ryoho. 2021 Jan;48(1):81-83.
4
The winning formulation: the development of paclitaxel in pancreatic cancer.
Clin Cancer Res. 2013 Oct 15;19(20):5572-9. doi: 10.1158/1078-0432.CCR-13-1356. Epub 2013 Aug 5.
5
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):479-80. doi: 10.1056/NEJMc1314761.
6
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):478. doi: 10.1056/NEJMc1314761.
7
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
N Engl J Med. 2014 Jan 30;370(5):478-9. doi: 10.1056/NEJMc1314761.
8
[Long-Term Survival following Multidisciplinary Therapy for Unresectable Pancreatic Body Cancer].
Gan To Kagaku Ryoho. 2022 Dec;49(13):1814-1816.
9
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
Int J Cancer. 2019 Mar 1;144(5):981-990. doi: 10.1002/ijc.31751. Epub 2018 Oct 3.
10
Advancements in the management of pancreatic cancer: 2013.
JOP. 2013 Mar 10;14(2):112-8. doi: 10.6092/1590-8577/1481.
引用本文的文献
1
A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?
Ther Adv Med Oncol. 2024 Jul 26;16:17588359241265213. doi: 10.1177/17588359241265213. eCollection 2024.
2
A case of pancreatic mucinous cystadenocarcinoma with malignant ascites without recurrence for more than 8 years after surgery.
Clin J Gastroenterol. 2022 Aug;15(4):834-839. doi: 10.1007/s12328-022-01639-z. Epub 2022 May 11.
本文引用的文献
1
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
BMC Cancer. 2020 May 20;20(1):449. doi: 10.1186/s12885-020-06945-8.
2
Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer.
World J Gastrointest Oncol. 2018 Dec 15;10(12):505-515. doi: 10.4251/wjgo.v10.i12.505.
3
Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines.
Visc Med. 2018 Jul;34(3):173-177. doi: 10.1159/000489641. Epub 2018 Jun 8.
4
Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
Cancer Commun (Lond). 2018 Jun 4;38(1):32. doi: 10.1186/s40880-018-0304-1.
5
Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.
Pancreas. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.
6
European evidence-based guidelines on pancreatic cystic neoplasms.
Gut. 2018 May;67(5):789-804. doi: 10.1136/gutjnl-2018-316027. Epub 2018 Mar 24.
7
Mucinous cystic neoplasms of the pancreas: high-resolution cross-sectional imaging features with clinico-pathologic correlation.
Abdom Radiol (NY). 2018 Jun;43(6):1413-1422. doi: 10.1007/s00261-017-1326-x.
8
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Medicine (Baltimore). 2017 May;96(19):e6769. doi: 10.1097/MD.0000000000006769.
9
Association of Preoperative Risk Factors With Malignancy in Pancreatic Mucinous Cystic Neoplasms: A Multicenter Study.
JAMA Surg. 2017 Jan 1;152(1):19-25. doi: 10.1001/jamasurg.2016.3598.
10
Nature and management of pancreatic mucinous cystic neoplasm (MCN): A systematic review of the literature.
Pancreatology. 2016 Nov-Dec;16(6):1028-1036. doi: 10.1016/j.pan.2016.09.011. Epub 2016 Sep 20.
Zotero 插件
